

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSIDE INFORMATION

GLOBAL EXCLUSIVE LICENSE AGREEMENT WITH ROCHE FOR QX031N

This announcement is made by Qyuns Therapeutics Co., Ltd. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) is pleased to announce that on October 28, 2025, the Company entered into a global exclusive collaboration and license agreement (the “**Agreement**”) with F. Hoffmann-La Roche Ltd (“**Roche**”), pursuant to which the Company grants Roche the global exclusive right to develop, manufacture, and commercialize QX031N (the “**Product**”).

The Company will receive a one-time, non-refundable, and non-creditable upfront payment of US\$75 million and is eligible to receive up to US\$995 million milestone payments associated with the development, regulatory approval, and commercialization of the product, as well as tiered royalties on potential future product sales.

ABOUT QX031N

QX031N is an investigational long-acting bispecific antibody that targets both human thymic stromal lymphopoietin (TSLP) and human interleukin-33 (IL-33).

TSLP and IL-33 are proteins called alarmins that are released in the body in response to external factors such as allergens, viruses, pollution, and mechanical stimuli. They have been shown to be involved in respiratory diseases like chronic obstructive pulmonary disease (“**COPD**”) and asthma, and play important roles in the inflammatory processes. QX031N is expected to be developed for the treatment of respiratory diseases such as COPD and asthma, and holds the potential to become a “First-in-class” and “Best-in-disease” therapy.

ABOUT ROCHE

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics.

LISTING RULES IMPLICATIONS

To the best knowledge, information and belief of the Company, having made all reasonable enquiries, Roche and its ultimate beneficial owners are independent of and not connected with the Company and its connected persons (as defined in the Listing Rules). The transactions contemplated under the Agreement are transactions of a revenue nature carried out in the ordinary and usual course of business of the Company and do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

The Agreement is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of the United States and any necessary regulatory filings. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Qyuns Therapeutics Co., Ltd.
Mr. Qiu Jiwan
Chairman of the Board and Executive Director

Hong Kong, October 28, 2025

As at the date of this announcement, the Board comprises Mr. Qiu Jiwan as chairman and executive director, Mr. Wu Yiliang and Mr. Lin Weidong as executive directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive Directors.